Payer Evidence · Health Economics · Market Access
Wamukelekile
Welcome, you all the travelers of the world. Uthando Nethemba reads clinical trials and health-policy signals closely — turning them into decision-ready notes on evidence, health economics, and market access.
Latest from the Blog
REMODEL’s Primary Kidney-Imaging Endpoints Were Null. The “Mechanism” Story Comes From Secondary and Exploratory Layers Instead
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers two peer-reviewed randomized trials of incretin-axis drugs, both industry-sponsored. Every number below is attributed to its source tier — peer-reviewed full text, a public trial registry, or a sponsor statistical…
NHS-Galleri’s Primary Endpoint Was Negative. A Day Later, FDA’s Panel Voted Yes. They Were Answering Different Questions, About Different Devices
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers a peer-reviewed randomized trial and a public regulatory advisory-committee record for a listed company’s screening test. Every number below is attributed to its source tier — peer-reviewed abstract, FDA public…
Continuous Atom Reloading in Neutral-Atom Qubits: A Subsystem Result, Not Yet a Fault-Tolerant One
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers a peer-reviewed physics paper describing one subsystem of a neutral-atom quantum computer: how quickly a lost or used-up atomic qubit can be replaced from a reservoir without disturbing the qubits…
Get new content delivered directly to your inbox.
